Spectrum and Cell Therapeutics form JV for projected expansion in US sales of Zevalin
The USA's Spectrum Pharmaceuticals and Cell Therapeutics have formed a 50/50 joint venture to market Zevalin ([90Y]-ibritumomab tiuxetan) in the USA.
The new entity, RIT Oncology, will sell the radioimmunotherapeutic in the USA, where it is currently marketed by CT for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including rituximab-refractory follicular NHL.
In afternoon trading on November 26, the day the news was announced, Spectrum shares jumped 8.2% to $1.45, while CT inched up less than one cent to $0.16 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze